Equities: The AI and obesity rally is defying gravity Equities: The AI and obesity rally is defying gravity Equities: The AI and obesity rally is defying gravity

Equities: The AI and obesity rally is defying gravity

Peter Garnry

Head of Equity Strategy

Summary:  Amid AI and obesity drug excitement, equities see varied prospects: neutral on overvalued US stocks, negative on Japan due to JPY risks, positive on Europe. European defence stocks gain appeal.

How much can the rubber band be stretched?

A benign economic backdrop combined with investor excitement over generative artificial intelligence (AI) and the new class of obesity drugs from Eli Lilly and Novo Nordisk have set in motion a speculative fever. The result is nothing but stunning. In no time, Nvidia has been catapulted to become the third most valuable company in the US worth $2.2trn and Novo Nordisk has become Europe’s most valuable company worth $600bn. Next to these stories there is an entire ecosystem of AI related companies, and obesity and biotechnology companies thriving on this boom in innovation. And not to forget the Magnificent Seven

Excitement always drive greed and extrapolation of expectations to unsustainable levels. This time is no different. As of February 2024, the US equity market hit valuation levels not seen since the dot-com and 2021 technology bubbles. Historically, the current equity valuation has led to low equity returns after subtracting inflation over the subsequent 10 years. Since December 2021, US equities are only up 5.2% and US CPI Index is up 10.6% as of January 2024. With US equities at their current equity valuations it is not the time to get greedy. In fact, investors should think about reducing their US equity exposure. Of course, we could be horribly wrong and the rubber band stretches even further.

No where to hide, or what?

The stretched valuation in US equities makes us tactically go neutral against a strategically positive view on US equities. While many negative things can be said of Europe the fiscal valves are being opened and the European equity market has some catchup to do relative to US and Japanese equities so our view is that a geography rotation into Europe could happen in Q2. We maintain negative view short term on Japanese equities due to JPY risks and BoJ pivot on policy rate.

On a sector level we are positive on energy (great value and good inflation hedge), health care (strong growth relative to valuation), and financials (favourable valuation and still good operating environment). We are negative on industrials (low growth and expensive), information technology (too much speculation and hype in the short term), utilities (low momentum and negative outlook), and real estate (low momentum and expensive).

Conviction: European defence stocks as US election looms

This year is biggest election year in modern history with the US election on 5 November being the most important election and especially for Europe. Biden and Trump are polling on par for the general election in the two most recent large polls, and Trump is questioning NATO and military support for Europe, keeping European politicians anxious with a more assertive Russia.

Regardless of whether Trump wins or not his comments about NATO have set off alarm bells in Europe’s capitals and mobilized efforts to dramatically increase military spending. Poland is already spending 4% of GDP and is willing to spend more. With military spending targets presented in Europe to go well beyond 2% of GDP a lot of growth is coming “Europe first” military spending benefitting European defence companies. Rheinmetall, Germany’s largest defence company, is expected to grow revenue by at least 18% annualised over the next five years. One of our biggest convictions is European defence companies.

How can investors get exposure to defence stocks? Investors can get inspiration from our defence theme basket or check out the various ETFs such as Future of Defence UCITS ETF or VanEck Defence UCITS ETF.


Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.